Drugs / Naderin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07671547 | Jan 2014 → Dec 2015 | breast cancer, chemotherapy-induced toxicity, leukopenia | MIPO Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT07671508 | May → Sep 2013 | cancer, hepatitis C virus infection, tuberculosis | MIPO Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naderin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07671547 ↗ |
| Route | Other | “It is administered locally alongside each chemotherapy cycle as prophylaxis against hematologic and immunologic complications.” NCT07671547 ↗ |